FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1086-1089 March 9, 2006 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Bradley, T. D. Related Article by Yaggi, H. K.

To the Editor: Bradley and colleagues (Nov. 10 issue)¹ report that treatment with continuous positive airway pressure (CPAP) in patients with heart failure and central sleep apnea did not affect morbidity and mortality, although several functional measures significantly improved. During the period of their study (the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure [CANPAP] trial), the primary event rate (death and cardiac transplantation) fell significantly. As discussed, this improvement was paralleled by a changing pattern of drug therapy for heart failure. Unfortunately, the use of implantable cardioverter–defibrillators and pacemakers for cardiac-resynchronization therapy was . . . [Full Text of this Article]

This article has been cited by other articles:

• Nakagawa, Y., Kishida, K., Kihara, S., Sonoda, M., Hirata, A., Yasui, A., Nishizawa, H., Nakamura, T., Yoshida, R., Shimomura, I., Funahashi, T. (2008). Nocturnal reduction in circulating adiponectin concentrations related to hypoxic stress in severe obstructive sleep apnea-hypopnea syndrome. Am. J. Physiol. Endocrinol. Metab. 294: E778-E784 [Abstract] [Full Text]